Diagnostic and prognostic value of serum L1-cell adhesion molecule in esophageal squamous cell carcinoma

Objective

L1 cell adhesion molecule (L1CAM) has been found to be dysregulated in several types of human cancers. Here, we aimed to determine the level of soluble L1CAM in serum of patients with esophageal squamous cell carcinoma (ESCC).

Methods

Serum levels of L1CAM were determined by an enzyme-linked immunosorbent assay (ELISA) in 191 patients with ESCC and 94 normal controls. Receiver operating characteristics (ROC) was employed to calculate diagnostic accuracy. Cumulative survival time was calculated by the Kaplan–Meier method and analyzed by the logrank test.

Results

Levels of L1CAM were significantly lower in all ESCC patients than in normal controls (P?<?0.001). Detection of serum L1CAM provided a sensitivity of 28.3%, a specificity of 90.4% and an area under the curve (AUC) of 0.644 (95% CI: 0.579–0.710) in diagnosing ESCC. Similar results were observed in the diagnosis of early-stage ESCC (26.2% sensitivity, 90.4% specificity, and an AUC of 0.629). Moreover, decreased level of L1CAM was correlated with depth of tumor invasion (P?<?0.05). Kaplan–Meier analysis showed that lower serum L1CAM level was significantly related to shorter overall survival time (P?=?0.036) and disease-free survival time (P?=?0.021) of ESCC patients.

Conclusions

Our study demonstrated that serum L1CAM might serve as a potential biomarker for the diagnosis and prognosis of ESCC.